U.S. Markets closed

Titan Pharmaceuticals, Inc. (TTNP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.600.00 (0.00%)
At close: 4:00PM EDT
People also watch
VNDABDSIIMUCONCSNAVB
Full screen
Previous Close1.60
Open1.60
Bid1.40 x 1000
Ask1.80 x 2000
Day's Range1.55 - 1.60
52 Week Range1.30 - 6.11
Volume51,165
Avg. Volume129,397
Market Cap33.93M
Beta1.72
PE Ratio (TTM)-2.62
EPS (TTM)-0.61
Earnings DateMay 11, 2017 - May 12, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Titan Pharmaceuticals To Present At Cantor Fitzgerald Global Healthcare Conference
    PR Newswire4 days ago

    Titan Pharmaceuticals To Present At Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 20, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that Titan President and CEO Sunil Bhonsle will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, Sept. 27 at 9:45 a.m. EDT at the Intercontinental New York Barclay Hotel. Mr. Bhonsle will review the company's ProNeura-based pipeline of clinical and early-stage product candidates, as well as provide a market update on Probuphine for the maintenance treatment of opioid dependence.

  • Titan Pharmaceuticals Receives FDA Clearance To Begin Clinical Study Of Parkinson's Disease Treatment
    PR Newswirelast month

    Titan Pharmaceuticals Receives FDA Clearance To Begin Clinical Study Of Parkinson's Disease Treatment

    SOUTH SAN FRANCISCO, Calif., Aug. 24, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease. "New treatments that offer continuous delivery of medication providing non-pulsatile stimulation of dopamine receptors in the brain appear to have some advantages over oral formulations," said Dr. Aaron Ellenbogen of the Michigan Institute of Neurological Disorders, and the principal investigator at the first trial site, near Detroit, Michigan.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TTNP earnings conference call or presentation 9-Aug-17 8:15pm GMT

    Q2 2017 Titan Pharmaceuticals Inc Earnings Call